Provided by Tiger Trade Technology Pte. Ltd.

Bavarian Nordic A/S

30.51
0.0000
Volume:- -
Turnover:- -
Market Cap:2.37B
PE:16.61
High:30.51
Open:30.51
Low:30.51
Close:30.51
52wk High:37.61
52wk Low:20.71
Shares:77.83M
Float Shares:77.67M
Volume Ratio:0.02
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.84
EPS(LYR):2.85
ROE:20.51%
ROA:7.78%
PB:1.23
PE(LYR):10.70

Loading ...

Company Profile

Company Name:
Bavarian Nordic A/S
Exchange:
PINK LIMITED
Establishment Date:
1992
Employees:
1738
Office Location:
Philip Heymans Alle 3,Hellerup,Capital Region of Denmark,Denmark
Zip Code:
2900
Fax:
- -
Introduction:
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.